Eight-year results of the Spiesser study, a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation.

摘要: We present the results at 8 years of Spiesser study, a randomized trial comparing de novo sirolimus and cyclosporine in kidney transplant recipients low immunologic risk. assessed estimated glomerular filtration (eGFR), graft, patient, death-censored graft survival (log-rank compared), DSA appearance, risk malignancy, post-transplant diabetes mellitus (PTDM), anemia. Intent-to-treat on-treatment analyses were performed. Graft was similar both groups (sirolimus: 73.3%, cyclosporine: 77.7, P = 0.574). No difference observed between treatment concerning patient (P 0.508) 0.858). In conditional intent-to-treat analysis, mean eGFR greater than group (62.5 ± 27.3 ml/min vs. 47.8 17.1 ml/min, 0.004), particular because function excellent patients maintained under (eGFR 74.0 ml/min). Importantly, no detrimental impact whom has been withdrawn 49.5 Overall, 17 showed DSAs, with two 0.520). Malignancy did not differ by treatment. An initial maintenance regimen based on provides long-term improvement renal for patients, especially those sirolimus.